T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Doximity
DOCS
$4.74B
| $416M | 0.04% |
5,156,496
+911,887
| +21% | +$66.7M |
|
377
Fox Class B
FOX
$24.4B
| $414M | 0.04% |
11,145,416
+72,178
| +0.7% | +$2.48M |
|
378
Zebra Technologies
ZBRA
$18B
| $410M | 0.04% |
795,657
-174,868
| -18% | -$97.4M |
|
379
Halliburton
HAL
$27.4B
| $409M | 0.04% |
18,935,071
-2,301,411
| -11% | -$47.1M |
|
380
Popular Inc
BPOP
$11.3B
| $409M | 0.04% |
5,269,958
-18,170
| -0.3% | -$1.35M |
|
381
Freshpet
FRPT
$3.5B
| $408M | 0.04% |
2,856,485
+656,625
| +30% | +$93.9M |
|
382
Insmed
INSM
$27.6B
| $406M | 0.04% |
14,740,432
+367,747
| +3% | +$9.65M |
|
383
Sysco
SYY
$40B
| $403M | 0.04% |
5,129,394
-49,354
| -1% | -$3.76M |
|
384
Opendoor
OPEN
$3.54B
| $400M | 0.04% |
20,151,680
+4,188,679
| +26% | +$67.7M |
|
385
Kemper
KMPR
$1.59B
| $399M | 0.04% |
5,980,909
+853,281
| +17% | +$57.9M |
|
386
Cameco
CCJ
$42.6B
| $397M | 0.04% |
18,270,302
-1,978,103
| -10% | -$37.4M |
|
387
Lowe's Companies
LOW
$122B
| $397M | 0.04% |
1,955,660
-439,289
| -18% | -$87.5M |
|
388
Guardant Health
GH
$21.4B
| $395M | 0.04% |
3,156,923
+1,577,628
| +100% | +$187M |
|
389
Ionis Pharmaceuticals
IONS
$9.28B
| $394M | 0.04% |
11,737,321
-521,506
| -4% | -$19.6M |
|
390
Leidos
LDOS
$17.9B
| $393M | 0.04% |
4,083,310
+205,595
| +5% | +$20.4M |
|
391
Xcel Energy
XEL
$49.3B
| $389M | 0.04% |
6,229,052
+2,151,129
| +53% | +$145M |
|
392
Adaptive Biotechnologies
ADPT
$3.89B
| $389M | 0.04% |
11,446,222
+479,331
| +4% | +$17.3M |
|
393
Altria Group
MO
$109B
| $385M | 0.04% |
8,459,549
-68,396
| -0.8% | -$3.3M |
|
|
THS
394
DELISTED
Treehouse Foods
THS
| $382M | 0.04% |
9,581,158
-244,567
| -2% | -$10M |
|
395
Regency Centers
REG
$14.1B
| $381M | 0.04% |
5,661,970
-165,006
| -3% | -$10.9M |
|
396
Northern Trust
NTRS
$34.8B
| $379M | 0.04% |
3,517,847
+34,437
| +1% | +$3.91M |
|
397
Bankunited
BKU
$3.41B
| $377M | 0.04% |
9,026,347
-442,770
| -5% | -$18.1M |
|
398
Roku
ROKU
$22.9B
| $376M | 0.04% |
1,200,647
-5,650
| -0.5% | -$2.13M |
|
|
MRTX
399
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $374M | 0.04% |
2,114,210
+192,431
| +10% | +$31M |
|
|
OCDX
400
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $367M | 0.03% |
19,865,900
+4,069,037
| +26% | +$81.9M |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.